Oncology Resources
Let's collaborate Boehringer Ingelheim

Oncology Resources

Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links to find further resources on key clinical data for afatinib and nintedanib, and the latest information on tumor types in which clinical investigations have been done or are ongoing.

PATIENT SUPPORT

Details of Boehringer Ingelheim patient support programs, including the MyStudyWindow clinical trials explorer and the ‘Taking Cancer on Through Flavor’ initiative

SLIDE BANK

A downloadable library of slide decks covering a variety of topics on different cancer types and therapeutic strategies

DOWNLOAD LIBRARY

A collection of downloadable materials, including oncology backgrounders, *afatanib and **nintedanib clinical trial summaries, data visualizations, and other resources

RELATED INFORMATION

AFATINIB

Afatinib (GIOTRIF®) is approved for the first-line treatment of patients with advanced/metastatic NSCLC with EGFR mutations, and patients with advanced/metastatic NSCLC of squamous histology after platinum-based chemotherapy

NINTEDANIB

Nintedanib (VARGATEF®) is approved in the EU and in other countries in combination with docetaxel for the treatment of patients with advanced/metastatic NSCLC of adenocarcinoma histology after first-line chemotherapy

NCCN Guidelines®

International adaptations and translations of the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)†
Back to top

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

 

† Linked with permission from National Comprehensive Cancer Network® (NCCN®).

© 2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: August 2020